These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2619974)

  • 41. Moclobemide--placebo-controlled trials.
    Silverstone T
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):133-6. PubMed ID: 8468433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Australian multicentre moclobemide trial.
    Stanton J
    Aust N Z J Psychiatry; 1993 Mar; 27(1):158. PubMed ID: 8481158
    [No Abstract]   [Full Text] [Related]  

  • 44. Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study.
    Rimón R; Jääskeläinen J; Kaartinen P; Kalli A; Kilponen E; Koskinen T; Nikkilä H; Pirttiperä V; Seppälä J
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):141-7. PubMed ID: 8468435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thyroid functioning during treatment for depression.
    Kusalic M; Engelsmann F; Bradwejn J
    J Psychiatry Neurosci; 1993 Nov; 18(5):260-3. PubMed ID: 8297924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
    Markianos M; Alevizos B; Hatzimanolis J; Stefanis C
    Psychiatry Res; 1994 Jun; 52(3):259-64. PubMed ID: 7527564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.
    Williams R; Edwards RA; Newburn GM; Mullen R; Menkes DB; Segkar C
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):155-8. PubMed ID: 8468437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine.
    Lonnqvist J; Sintonen H; Syvälahti E; Appelberg B; Koskinen T; Mannikko T; Mehtonen OP; Naarala M; Sihvo S; Auvinen J
    Acta Psychiatr Scand; 1994 Jun; 89(6):363-9. PubMed ID: 8085464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial.
    Larsen JK; Holm P; Mikkelsen PL
    Acta Psychiatr Scand; 1984 Sep; 70(3):254-60. PubMed ID: 6388247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany.
    Funke HJ; Moritz E; Hellstern K; Malanowski H
    Acta Psychiatr Scand Suppl; 1990; 360():46-7. PubMed ID: 2248069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP; Tsoi WF
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.
    Botte L; Evrard JL; Gilles C; Stenier P; Wolfrum C
    Acta Psychiatr Belg; 1992; 92(6):355-69. PubMed ID: 1345409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia.
    Pétursson H
    Acta Psychiatr Scand Suppl; 1995; 386():36-9. PubMed ID: 7717093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of moclobemide in endogenous depression: a survey of recent data.
    Woggon B
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):137-9. PubMed ID: 8468434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Moclobemide, imipramine and placebo in the treatment of major depression.
    Versiani M; Nardi AE; Mundim FD; Alves A; Schmid-Burgk W
    Acta Psychiatr Scand Suppl; 1990; 360():57-8. PubMed ID: 2248073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes].
    Barrelet L; Blajev B; Bolzani L; de Saussure C; Kasas A; Van H; Gachoud JP
    Schweiz Rundsch Med Prax; 1991 May; 80(19):524-8. PubMed ID: 1904620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. A Study group.
    Lecrubier Y; Pedarriosse AM; Payan C; Schmid-Burgk W; Stabl M
    Acta Psychiatr Scand; 1995 Oct; 92(4):260-5. PubMed ID: 8848950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Moclobemide (Ro 11-1163) versus tranylcypromine in the treatment of endogenous depression.
    Gabelic I; Kuhn B
    Acta Psychiatr Scand Suppl; 1990; 360():63. PubMed ID: 2248076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.